Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 1, 2006

Santhera and University of Basel Join NMD Network

  • Santhera Pharmaceuticals and the University of Basel’s Biozentrum research unit are joining a pan-European network of excellence known as TREAT-NMD (Translational Research in Europe—Assessment and Treatment of NeuroMuscular Diseases), which aims to coordinate research into rare neuromuscular diseases and accelerate the development of new therapeutics.

    TREAT-NMD is being funded by a five-year, EUR10-million E.U. grant and involves academic and commercial organizations in 11 European countries. Santhera is leading part of the TREAT-NMD program focused on accelerating preclinical development of new therapeutics. The company’s role includes identifying the most disease-relevant efficacy parameters and developing standardized protocols and procedures for harmonizing and accelerating preclinical studies of drug candidates. In parallel, researchers at the Biozentrum will select appropriate preclinical disease models.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »